X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38607) 38607
Newsletter (2917) 2917
Newspaper Article (2709) 2709
Magazine Article (369) 369
Book Chapter (127) 127
Transcript (70) 70
Dissertation (20) 20
Book Review (10) 10
Book / eBook (9) 9
Reference (9) 9
Government Document (8) 8
Web Resource (6) 6
Streaming Video (5) 5
Publication (4) 4
Conference Proceeding (3) 3
Report (3) 3
Trade Publication Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29691) 29691
antiviral agents (20105) 20105
female (15283) 15283
male (14919) 14919
antiviral agents - therapeutic use (13590) 13590
adult (11034) 11034
antiviral agents - administration & dosage (10893) 10893
middle aged (9719) 9719
animals (7811) 7811
health aspects (7675) 7675
drug therapy (7604) 7604
hiv (6804) 6804
infectious diseases (6787) 6787
treatment outcome (6611) 6611
infection (5530) 5530
research (5427) 5427
drug therapy, combination (5425) 5425
virology (5366) 5366
dosage and administration (5363) 5363
pharmacology & pharmacy (5334) 5334
care and treatment (4869) 4869
immunology (4815) 4815
viruses (4805) 4805
hepatitis c, chronic - drug therapy (4741) 4741
aids (4715) 4715
hiv infections - drug therapy (4658) 4658
aged (4514) 4514
antiviral agents - pharmacology (4366) 4366
gastroenterology & hepatology (4327) 4327
therapy (4257) 4257
hepatitis c (4249) 4249
infections (4212) 4212
hiv infection (4143) 4143
analysis (4106) 4106
antiviral agents - adverse effects (4002) 4002
microbiology (3867) 3867
virus diseases (3849) 3849
interferon (3602) 3602
risk factors (3578) 3578
human immunodeficiency virus--hiv (3532) 3532
mice (3461) 3461
hepatitis c virus (3404) 3404
anti-hiv agents (3265) 3265
adolescent (3203) 3203
viral load (3171) 3171
hepatitis (3099) 3099
ribavirin (3050) 3050
prevention (2890) 2890
interferon-alpha - therapeutic use (2680) 2680
interferon-alpha - administration & dosage (2652) 2652
ribavirin - administration & dosage (2645) 2645
research article (2623) 2623
young adult (2590) 2590
highly active antiretroviral therapy (2579) 2579
genotype (2538) 2538
medicine (2537) 2537
antiretroviral therapy (2524) 2524
ribavirin - therapeutic use (2500) 2500
hepacivirus - genetics (2419) 2419
medical research (2409) 2409
time factors (2374) 2374
retrospective studies (2268) 2268
recombinant proteins (2264) 2264
influenza (2177) 2177
drugs (2166) 2166
child (2162) 2162
hepatitis c - drug therapy (2134) 2134
hepatitis b (2133) 2133
drug administration schedule (2070) 2070
patients (2018) 2018
transplantation (1999) 1999
medicine, general & internal (1970) 1970
mortality (1958) 1958
multidisciplinary sciences (1947) 1947
administration, oral (1938) 1938
usage (1917) 1917
hepatitis b, chronic - drug therapy (1902) 1902
disease (1859) 1859
medicine, experimental (1853) 1853
liver (1852) 1852
anti-hiv agents - therapeutic use (1825) 1825
antiretroviral drugs (1813) 1813
clinical trials (1809) 1809
hiv patients (1788) 1788
medicine & public health (1777) 1777
acquired immune deficiency syndrome--aids (1770) 1770
pharmaceutical industry (1758) 1758
replication (1736) 1736
virus (1721) 1721
antiviral activity (1720) 1720
efficacy (1720) 1720
hepacivirus - drug effects (1710) 1710
virus-infection (1703) 1703
antiviral therapy (1674) 1674
antiviral agents - pharmacokinetics (1654) 1654
abridged index medicus (1641) 1641
science (1629) 1629
dose-response relationship, drug (1628) 1628
prospective studies (1609) 1609
human immunodeficiency virus (1586) 1586
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42979) 42979
Japanese (392) 392
Russian (318) 318
German (292) 292
French (291) 291
Chinese (276) 276
Spanish (243) 243
Polish (85) 85
Hungarian (48) 48
Korean (48) 48
Italian (40) 40
Danish (34) 34
Dutch (29) 29
Portuguese (27) 27
Swedish (24) 24
Czech (21) 21
Croatian (17) 17
Norwegian (14) 14
Romanian (10) 10
Ukrainian (10) 10
Serbian (9) 9
Hebrew (7) 7
Arabic (5) 5
Turkish (5) 5
Bulgarian (4) 4
Finnish (4) 4
Slovak (3) 3
Bosnian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e105653
.... We estimated the relative efficacy and safety of dolutegravir (DTG) versus third agents currently recommended by guidelines, including ritonavir-boosted atazanavir (ATV/r... 
REVERSE-TRANSCRIPTASE INHIBITOR | ANTIRETROVIRAL-NAIVE | TENOFOVIR DISOPROXIL FUMARATE | MULTIDISCIPLINARY SCIENCES | DAILY DARUNAVIR/RITONAVIR | CO-FORMULATED ELVITEGRAVIR | HIV TYPE-1 INFECTION | DOUBLE-BLIND | ONCE-DAILY ATAZANAVIR/RITONAVIR | INITIAL TREATMENT | TWICE-DAILY LOPINAVIR/RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Rilpivirine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | HIV Infections - immunology | Time Factors | Lipids - blood | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Treatment Outcome | CD4 Lymphocyte Count | Adenine - administration & dosage | Randomized Controlled Trials as Topic | Organophosphonates - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Lopinavir - administration & dosage | HIV Infections - drug therapy | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | RNA | Low density lipoproteins | Analysis | DNA polymerases | Triglycerides | HIV (Viruses) | Drug therapy | HIV infection | Backbone | Lipoproteins (low density) | RNA-directed DNA polymerase | Identification methods | Ritonavir | Clinical trials | Efavirenz | Impact analysis | Literature reviews | Randomization | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mathematical models | Safety | All terrain vehicles | Medical research | Antiretroviral drugs | Sensitivity analysis | Effectiveness | Lopinavir | Lamivudine | Ribonucleic acid--RNA | Patients | Cholesterol | CD4 antigen | Studies | Inhibitors | Abacavir | Nucleosides | Bayesian analysis | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2013, Volume 38, Issue 2, pp. 98 - 106
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
[Display omitted] Clinical trials evaluating second-generation direct-acting antiviral agents (DAAs... 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2011, Volume 52, Issue 11, pp. 1374 - 1383
Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)—associated tuberculous meningitis is unknown.... 
Statistical median | HIV/AIDS | Antiretrovirals | Art therapy | Meningeal tuberculosis | HIV | Mortality | Random allocation | AIDS | Arts | HIV 1 | MORTALITY | SURVIVAL | THAILAND | INFECTIOUS DISEASES | HIV-INFECTION | ERA | ADOLESCENTS | CLINICAL-TRIALS | ADULTS | RISK | MICROBIOLOGY | IMMUNOLOGY | Lamivudine - administration & dosage | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Time Factors | Adult | Anti-Inflammatory Agents - administration & dosage | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | Tuberculosis, Meningeal - mortality | Placebos - administration & dosage | Dexamethasone - administration & dosage | Tuberculosis, Meningeal - drug therapy | Benzoxazines - administration & dosage | Double-Blind Method | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Anti-HIV Agents - adverse effects | Treatment Outcome | Tuberculosis, Meningeal - complications | HIV Infections - complications | Antitubercular Agents - administration & dosage | HIV Infections - drug therapy | Antiviral agents | Care and treatment | Patient outcomes | Dosage and administration | Drug therapy | Health aspects | HIV infection | Comorbid patients | Tuberculous meningitis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 10, pp. 913 - 923
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
..., post-transplant HCV infection, hemodialysis patients, and others [3]. The HCV protease inhibitor BILN 2061 was the first agent in man to specifically target HCV... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | PLUS RIBAVIRIN | BILN-2061 | TELAPREVIR | EFFICACY | VX-950 | HEPATITIS-C-VIRUS | IN-VITRO | EARLY ANTIVIRAL ACTIVITY | PEGINTERFERON ALPHA-2A | ATAZANAVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 4, pp. 872 - 884
... and in vivo expression of both CYP3A4/5 and P-gp vary substantially between individuals [1–6] . As a result, administration of a drug that is a CYP3A or P-gp substrate... 
Gastroenterology and Hepatology | Immunosuppression | Antiviral therapy | Hepatitis C | Cytochrome P450 | Calcineurin inhibitors | PHARMACOKINETIC INTERACTION | PEGYLATED INTERFERON ALPHA-2A | PROTEASE INHIBITOR BOCEPREVIR | SUSTAINED VIROLOGICAL RESPONSE | GENOTYPE 1 | HEPATITIS-C VIRUS | CAUSALITY ASSESSMENT | SIMEPREVIR TMC435 | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Hepatitis C, Chronic - metabolism | Liver Transplantation - adverse effects | Humans | Immunosuppressive Agents - pharmacokinetics | Oligopeptides - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Interactions | Anti-Bacterial Agents - adverse effects | Chemical and Drug Induced Liver Injury - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Proline - administration & dosage | Proline - analogs & derivatives | Administration, Oral | Calcineurin Inhibitors - administration & dosage | Risk Factors | Hepatitis C, Chronic - surgery | Tacrolimus - pharmacokinetics | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Chemical and Drug Induced Liver Injury - diagnosis | Antiviral Agents - adverse effects | Proline - adverse effects | Oligopeptides - administration & dosage | Anti-Bacterial Agents - administration & dosage | Complications and side effects | Liver diseases | Protease inhibitors | Proteases | Liver | Drug interactions | Organ transplant recipients | Transplantation | Hepatitis C virus | Immunosuppressive agents | Index Medicus
Journal Article